Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Ambrosia Biosciences Inc. logo — Small molecule therapies for obesity and metabolic disorders...

Ambrosia Biosciences Inc.

Small molecule therapies for obesity and metabolic disorders, delivered orally

Founded 2024 United States Boulder, United States 38 employees Series B Total: $125.00M Biotechnology, Pharmaceutical

General Information

Company Name Ambrosia Biosciences Inc.
Founded Year 2024
Location United States Boulder, United States
Employees 38
Industries Biotechnology, Pharmaceutical
Funding Stage Series B
Business Model B2B, Platform
Revenue Model Licensing, Performance Based
Social

BounceWatch is an independent company data service, not affiliated with Ambrosia Biosciences Inc.. To contact Ambrosia Biosciences Inc., visit ambrosiabiosciences.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About Ambrosia Biosciences Inc.

Ambrosia Biosciences Inc., founded in 2024, is positioned at the forefront of tackling global health challenges in Biotechnology and Pharmaceutical industries. The company is pioneering the development of orally delivered, small molecule-based therapies to address pressing issues such as obesity and metabolic disorders.

The latest funding round, a $100.00M Series B investment secured on 01 March 2026, highlights strong market confidence and interest from reputable investors including Boulder Ventures, Redmile Group, Blue Owl Capital, BVF Partners, Deep Track Capital, Janus Henderson Investors, and Samsara BioCapital.

While Ambrosia Biosciences Inc. is still in its developmental phase without a specified headquarters, the strategic support manifested through this extensive investor network underscores its potential to revolutionize treatment paradigms in metabolic health.

Taxonomy: small molecule therapies, obesity treatment, metabolic disorders, drug discovery, orally delivered drugs, GLP-1, incretin hormones, class B GPCRs, therapeutics development, pharmaceutical innovation, novel drug compounds

Services & Products

Development of small molecule-based therapies
Drug discovery using structure-based approaches
Rapid iteration from initial discovery to IND filings
Discovery of orally delivered therapies for obesity

Target Customers

Biotechnology investors Pharmaceutical industry partners Patients with obesity and metabolic disorders Scientific community focusing on metabolic and cardiometabolic conditions

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series B $100.00M 7
Boulder Ventures Redmile Group Blue Owl Capital
Boulder Ventures, Redmile Group +5
01 Mar 2026
Series A $9.00M 3
Boulder Ventures BVF Partners Merck
Boulder Ventures, BVF Partners +1
01 Dec 2024
Series A $16.00M 2
Boulder Ventures BVF Partners
Boulder Ventures, BVF Partners
01 Aug 2024

Ambrosia Biosciences Inc. Alternatives & Competitors

Ambrosia Biosciences Inc. vs
Advenchen Laboratories, LLC
Advenchen Laboratories, LLC

Pioneering novel therapies with promising small molecule kinase inhibitors for a brighter future in...

Venture round
6 employees
Biotechnology, Health Care
Ambrosia Biosciences Inc. vs
Xanthus Pharmaceuticals
Xanthus Pharmaceuticals

Innovative treatments for cancer and autoimmune disorders through pioneering small-molecule therapeu...

Series B
Biopharma, Biotechnology
Ambrosia Biosciences Inc. vs
Helicore Biopharma
Helicore Biopharma United States

Long-Acting Medicines to Transform Metabolic Health

Series A
7 employees
Biotechnology, Pharmaceutical

FAQ About Ambrosia Biosciences Inc.

Small molecule therapies for obesity and metabolic disorders, delivered orally
Ambrosia Biosciences Inc. was founded in 2024.
Ambrosia Biosciences Inc. is headquartered in Boulder, United States.
Ambrosia Biosciences Inc. operates in Biotechnology and Pharmaceutical. Its work centres on small molecule therapies, obesity treatment, metabolic disorders and drug discovery. Its customers include Biotechnology investors, Pharmaceutical industry partners and Patients with obesity and metabolic disorders.
Ambrosia Biosciences Inc. has a B2B and Platform business model. Its revenue comes from Licensing and Performance Based.
Ambrosia Biosciences Inc. has approximately 38 employees.
Ambrosia Biosciences Inc. has completed 3 funding rounds, raising a total of $125.00M. The latest funding stage is Series B.
Ambrosia Biosciences Inc. offers: Development of small molecule-based therapies, Drug discovery using structure-based approaches, Rapid iteration from initial discovery to IND filings, Discovery of orally delivered therapies for obesity.
Top alternatives and competitors to Ambrosia Biosciences Inc. include Advenchen Laboratories, LLC, Xanthus Pharmaceuticals, Helicore Biopharma, Pharvaris, Sirtris Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Ambrosia Biosciences Inc. and Advenchen Laboratories, LLC are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Ambrosia Biosciences Inc., https://bouncewatch.com/company/ambrosia-biosciences-inc, updated 26 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes